MA42419A - Méthode de traitement de l'encéphalopathie hépatique - Google Patents

Méthode de traitement de l'encéphalopathie hépatique

Info

Publication number
MA42419A
MA42419A MA42419A MA42419A MA42419A MA 42419 A MA42419 A MA 42419A MA 42419 A MA42419 A MA 42419A MA 42419 A MA42419 A MA 42419A MA 42419 A MA42419 A MA 42419A
Authority
MA
Morocco
Prior art keywords
treatment
hepatic encephalopathy
encephalopathy
hepatic
biotin
Prior art date
Application number
MA42419A
Other languages
English (en)
Other versions
MA42419B1 (fr
Inventor
Frédéric Sedel
Original Assignee
Medday Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medday Pharmaceuticals filed Critical Medday Pharmaceuticals
Publication of MA42419A publication Critical patent/MA42419A/fr
Publication of MA42419B1 publication Critical patent/MA42419B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne l'utilisation de la biotine à une dose quotidienne d'au moins 100 mg pour le traitement de l'encéphalopathie hépatique.
MA42419A 2016-07-29 2017-07-28 Méthode de traitement de l'encéphalopathie hépatique MA42419B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305989.2A EP3275439A1 (fr) 2016-07-29 2016-07-29 Procédé de traitement de l'encéphalopathie hépatique
PCT/EP2017/069194 WO2018020010A1 (fr) 2016-07-29 2017-07-28 Méthode de traitement de l'encéphalopathie hépatique

Publications (2)

Publication Number Publication Date
MA42419A true MA42419A (fr) 2018-05-16
MA42419B1 MA42419B1 (fr) 2019-11-29

Family

ID=56618106

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42419A MA42419B1 (fr) 2016-07-29 2017-07-28 Méthode de traitement de l'encéphalopathie hépatique

Country Status (23)

Country Link
US (2) US10117854B2 (fr)
EP (2) EP3275439A1 (fr)
JP (1) JP2019522030A (fr)
KR (1) KR20190034550A (fr)
AU (1) AU2017303346A1 (fr)
BR (1) BR112019001178A2 (fr)
CA (1) CA3031302A1 (fr)
CY (1) CY1122348T1 (fr)
DK (1) DK3319601T3 (fr)
EA (1) EA201990413A1 (fr)
ES (1) ES2751154T3 (fr)
HK (1) HK1254833B (fr)
HR (1) HRP20191798T1 (fr)
HU (1) HUE046590T2 (fr)
IL (1) IL264460B (fr)
LT (1) LT3319601T (fr)
MA (1) MA42419B1 (fr)
ME (1) ME03520B (fr)
PL (1) PL3319601T3 (fr)
PT (1) PT3319601T (fr)
RS (1) RS59300B1 (fr)
SI (1) SI3319601T1 (fr)
WO (1) WO2018020010A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3275439A1 (fr) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Procédé de traitement de l'encéphalopathie hépatique
MX2018004788A (es) * 2018-04-18 2019-10-21 Alparis Sa De Cv Nuevas fases solidas de rifaximina.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788304B2 (ja) * 1988-03-05 1995-09-27 三生製薬株式会社 高アンモニア血症治療剤
US5814650A (en) * 1992-09-28 1998-09-29 Lifegroup S.P.A. Biotin amides able to control glucidic metabolisms under dysmetabolic conditions and relative therapeutical compositions
DE20202562U1 (de) * 2002-02-19 2002-05-23 Orthomol pharmazeutische Vertriebs GmbH, 40764 Langenfeld Mikronährstoffkombinationsprodukt mit Pro- und Prebiotika
US20040219188A1 (en) * 2003-05-02 2004-11-04 Comer Gail M. Composition and methods for nutritional management of patients with hepatic disease
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
CA2910717C (fr) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotine pour son utilisation dans le traitement d'une adrenoleucodystrophie liee a l'x
EP3072513A1 (fr) 2015-03-26 2016-09-28 Medday Biotin pour le traitement de la sclérose latérale amyotrophique
CN105614851A (zh) * 2015-12-27 2016-06-01 劲膳美生物科技股份有限公司 肝性脑病医学配方食品
EP3275439A1 (fr) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Procédé de traitement de l'encéphalopathie hépatique

Also Published As

Publication number Publication date
HUE046590T2 (hu) 2020-03-30
EA201990413A1 (ru) 2019-06-28
RS59300B1 (sr) 2019-10-31
US20190070150A1 (en) 2019-03-07
ES2751154T3 (es) 2020-03-30
SI3319601T1 (sl) 2019-11-29
PL3319601T3 (pl) 2020-06-29
US20180214417A1 (en) 2018-08-02
WO2018020010A1 (fr) 2018-02-01
HRP20191798T1 (hr) 2019-12-27
DK3319601T3 (da) 2019-11-18
LT3319601T (lt) 2019-11-11
AU2017303346A1 (en) 2019-01-31
ME03520B (fr) 2020-04-20
KR20190034550A (ko) 2019-04-02
EP3319601A1 (fr) 2018-05-16
MA42419B1 (fr) 2019-11-29
BR112019001178A2 (pt) 2019-04-30
CA3031302A1 (fr) 2018-02-01
PT3319601T (pt) 2019-09-18
IL264460B (en) 2021-06-30
US10117854B2 (en) 2018-11-06
EP3275439A1 (fr) 2018-01-31
US10328059B2 (en) 2019-06-25
CY1122348T1 (el) 2021-01-27
IL264460A (en) 2019-02-28
HK1254833B (zh) 2020-05-22
JP2019522030A (ja) 2019-08-08
EP3319601B1 (fr) 2019-08-28

Similar Documents

Publication Publication Date Title
MA55021A (fr) 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression
MA40755B1 (fr) Compositions comprenant des souches bactériennes
MA40754B1 (fr) Compositions comprenant des souches bactériennes
MA47719A (fr) Esketamine pour le traitement de la dépression
MA41013A (fr) Compositions comprenant des souches bactériennes
MA41060B1 (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA42471A (fr) Compositions comprenant des souches bactériennes
MA41010B1 (fr) Compositions comprenant des souches bactériennes
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA51203A (fr) Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MA46548A (fr) Fsh pour le traitement de l'infertilité
MA55218A (fr) Eskétamine pour le traitement de la dépression
MA43825A (fr) Schémas posologiques pour le traitement d'infections fongiques
MA49373B1 (fr) Compositions comprenant des souches bactériennes
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
MA42419A (fr) Méthode de traitement de l'encéphalopathie hépatique
MA45845A (fr) Traitement d'association pour cancers hématologiques
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
MA41809A (fr) Biotine pour le traitement de la sclérose latérale amyotrophique
FR3019465B1 (fr) Composition hyperosmolaire d'acide hyaluronique et son utilisation pour le traitement de l'oedeme corneen